Cited by 2,052Hepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus StudiesHead and Neck Cancer Studies

The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Open access

Singal, Amit G., Llovet, Josep M., Yarchoan, Mark, Mehta, Neil, Heimbach, Julie K., Dawson, Laura A., Jou, Janice H., Kulik, Laura M., Agopian, Vatche G., Marrero, Jorge A., Mendiratta-Lala, Mishal, Brown, Daniel B., Rilling, William S., Goyal, Lipika, Wei, Alice C., Taddei, Tamar H.·2023·Hepatology

DOI 10.1097/hep.0000000000000466PMC PMC10663390

Open this paper in CoChat — free account Open PDF

Abstract

Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000466

Cites

338 of 338 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
Influential
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Hepatocellular carcinoma
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citation
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”

Show all 341 references

Research works printed but not linked: 2

Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057

Sorted by citations

Items 401–500 of 1,000

A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma
Wang, C., Leng, B., You, R., Yu, Z., Ya, L., Diao, L., Jiang, H., Cheng, Y., Yin, G., & Xu, Q. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s480540 · Cited by 8
“15 Besides visible or measurable parameters in CT or MRI, visible imaging data can be converted into high-throughput and precise features through radiomics approach, and it has been extensively used in various cancer types for diagnosis and clinical outcome prediction.”
Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging
Li, Z., Mo, C., Li, C., Wang, Q., Huang, S., Huang, Y., & Liang, Y. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00504 · Cited by 8
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma
Ren, L., Chen, D. B., Yan, X., She, S., Yang, Y., Zhang, X., Liao, W., & Chen, H. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s423549 · Cited by 8
“96 Therefore, more refined stratification methods are required to meet the needs of precision treatment.”
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
Lam, B. P., Bartholomew, J., Bau, S., Gilles, H., Keller, A., Moore, A., Nader, K., Richards, L., Henry, L. L., & Younossi, Z. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002140 · Cited by 8
“10,68 Moreover, only 1.5 million of those with MASH have been diagnosed.”
Influential
Temporal trends of liver cancer burden, comparative analysis of risk factors and trend forecasts to 2024 in China, USA, the Republic of Korea, and Mongolia: an analysis based on multiple data sources from Global Burden of Disease 2019, the Global Cancer Observatory, and Cancer Incidence in Five Continents
Yao, X., Ling, X., Zhu, Z., cao, X., & Tang, S. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04040 · Cited by 8
Advancements in immunotherapy for hepatocellular carcinoma
Ascari, S., Chen, R., Vivaldi, C., Stefanini, B., Sinno, A. D., Dalbeni, A., Federico, P., & Tovoli, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461631 · Cited by 8
“The latest guidelines from the American Association for the Study of Liver Diseases recommend assessing bleeding risk from esophageal varices, with tremelimu-mab-durvalumab preferred as first-line therapy in high-risk patients, assuming immunotherapy remains appropriate [20].”
Ethanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death
Hsu, Y.-C., Wu, M.-C., Weng, M., Lee, Y.-T., Chou, H.-C., Lee, M., Wang, L., Sheu, J., & Chen, C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010472 · Cited by 8
Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC)
Anastasopoulos, N.-A., Barbouti, A., GOUSSIA, A. C., Christodoulou, D. K., & Glantzounis, G. K. (2025) · Cancers · doi:10.3390/cancers17050842 · Cited by 8
Improving Health-Related Quality of Life in Hepatocellular Carcinoma Patients: Key Methodologies for Assessing Patient Reported Outcomes and Intervention Targets
Moon, A. M., Kappelman, M. D., Barritt, A. S., Evon, D. M., Sanoff, H. K., & Wagner, L. I. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347929 · Cited by 9
“93,105 Additionally, referral of patients diagnosed with HCC to centers that can offer curative therapies including surgical resection and liver transplantation may improve these outcomes.”
LI-RADS-based hepatocellular carcinoma risk mapping using contrast-enhanced MRI and self-configuring deep learning
Stollmayer, R., Güven, S., Heidt, C. M., Schlamp, K., Kaposi, P. N., von Stackelberg, O., Kauczor, H., Klauß, M., & Mayer, P. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00844-6 · Cited by 8
“According to recent guidelines [1–4], the characteristic appearance of HCC with radiological imaging is sufficient for its diagnosis without the need for biopsy in patients who are at high risk for HCC and when there is curative intent.”
Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study
Chen, X., Wu, X., Peng, W., Liu, L., Liu, X., Wan, X., Xu, H., Zheng, Y., Zhao, H., Mao, Y., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s504016 · Cited by 8
Management of hepatocellular carcinoma in elderly and adolescent/young adult populations
Lee, H. A. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.02.28 · Cited by 8
“40 For surgical resection in elderly patients with HCC, careful consideration of age-related liver changes is required, as factors like reduced hepatic blood flow, diminished bile acid secretion, and impaired immune function can impact surgical outcomes and recovery.”
Single-Energy, Dual-Energy, and Photon-Counting Computed Tomography of the Liver: Current Development and Clinical Utility for the Assessment of Focal Liver Lesions
Ichikawa, S., Sofue, K., Nakamura, Y., Higaki, T., Morisaka, H., Hyodo, T., Murakami, T., Awai, K., Jinzaki, M., & Goshima, S. (2025) · Investigative Radiology · doi:10.1097/rli.0000000000001187 · Cited by 8
The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma
Norman, J. S., & Mehta, N. J. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00686-7 · Cited by 10
Self-citation
Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma
Artusa, F., Lamatsch, S., Phan, M. D., Özdirik, B., Berger, H., Egerer, M., Knorr‐Klocke, J., Fischer, J., Veelken, R., van Bömmel, F., et al. (2025) · Liver International · doi:10.1111/liv.70121 · Cited by 8
Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma
Ball, D., Nault, J., Vithayathil, M. K., Allaire, M., Ganne‐Carrié, N., Campani, C., Marra, F., & Sharma, R. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00908-7 · Cited by 8
“…had a histological or radiological diagnosis of HCC in accordance with either European Association for Study of the Liver (EASL) or American Association for the Study of Liver Diseases (AASLD) criteria 20,21 and were deemed suitable for A/B following local multidisciplinary meeting discussion.”
Robotic vs laparoscopic resection for hepatocellular carcinoma: multicentric propensity-score matched analysis of surgical and oncologic outcomes in 647 patients
Sandro, S. D., Centonze, L., Ratti, F., Russolillo, N., Conci, S., Gringeri, E., Ardito, F., Colasanti, M., Sposito, C., Carlis, R. D., et al. (2025) · Updates in Surgery · doi:10.1007/s13304-025-02293-z · Cited by 8
Artificial intelligence for multi-time-point arterial phase contrast-enhanced MRI profiling to predict prognosis after transarterial chemoembolization in hepatocellular carcinoma
Yao, L., Adwan, H., Bernatz, S., Li, H., & Vogl, T. J. (2025) · La radiologia medica · doi:10.1007/s11547-025-02043-6 · Cited by 8
Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives
Ding, W., Zhang, J.-X., Jin, Z., Hua, H. J., Zu, Q., Yang, S., Wang, W., Liu, S., Zhou, H.-F., & Shi, H.-B. (2025) · Discover Oncology · doi:10.1007/s12672-025-03254-z · Cited by 13
“According to the latest HCC management guidelines from the EASL and AASLD [47, 48], MVI, poor PG, and satellite nodules are traditionally recognized as high-risk pathological features [49].”
Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Ohara, M., Suda, G., Kohya, R., Yasui, Y., Tsuchiya, K., Kurosaki, M., Tani, J., Maekawa, S., Enomoto, N., Chuma, M., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10875-7 · Cited by 8
Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma
Kim, H. U., Han, J. W., Sung, P. S., Jang, J. W., Yoon, S. K., Choi, H. J., & You, Y. K. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.32353 · Cited by 8
State-of-the-Art Review: Hepatitis C
Re, V. L., Bhattacharya, D., Price, J. C., Aronsohn, A. I., Kim, H. N., Falade-Nwulia, O. O., Zimmerman, M., Trooskin, S. B., & Torgersen, J. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf334 · Cited by 8
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
Chan, S. L., Kudo, M., Sangro, B., Kelley, R. K., Kim, J. H., Pham, B. V., Hong, J. Y., Waldschmidt, D., Marino, D., Lee, J. J. X., et al. (2025) · Liver Cancer · doi:10.1159/000549955 · Cited by 8
Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular Carcinoma
Lu, M., Wu, J. C., Lu, H. H.-S., Eslam, M., & Yu, M. (2025) · Gut and Liver · doi:10.5009/gnl250268 · Cited by 8
AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review
Rich, N. E., Villanueva, A., Marrero, J. A., & Kanwal, F. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.03.006 · Cited by 9
Self-citation
Hepatic Precancerous Lesions and Early Hepatocellular Carcinoma
Wen, K. W., & Kakar, S. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.11.005 · Cited by 8
Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Huynh, H. T., Ng, W. H., & Soo, K. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010017 · Cited by 8
Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Ng, W. H., Soo, K. C., & Huynh, H. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031563 · Cited by 8
“…considered as preferable to ﬁrst-line therapy options [11], except for patients with high-risk stigmata of variceal or other gastrointestinal bleeding and those with liver cirrhosis in whom immune-based regimes are contraindicated (e.g., severe autoimmune disorders or liver transplantation) [12].”
Background
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy
Zheng, Z., Mei, J., Guan, R., Zhang, J., Xiong, X., Gan, J., Li, S., & Guo, R. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03713-6 · Cited by 8
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)
López, C., Calvo, M., Cámara, J. C., García-Paredes, B., Gómez-Martín, C., López, A. M., Pazo-Cid, R., Sastre, J., Yayá, R., & Feliú, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03568-4 · Cited by 8
“Alpha-fetoprotein (AFP) detection is slightly more sensitive and is cost-effective [13, 14], although there is no consensus concerning its use as a screening method [15, 16].”
Background
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma
Parikh, N. D., Jones, P., Salgia, R. J., Bhan, I., Grinspan, L. T., Jou, J. H., Zhou, K., Jalal, P. K., Roccaro, G. A., Rangnekar, A. S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.008 · Cited by 8
Self-citation
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Hsu, Y.-C., Lin, P., Teng, W., Hsieh, Y., Chen, W., Su, C., Wang, C., Chai, P., Lin, C., Lin, C.-Y., et al. (2024) · Cancers · doi:10.3390/cancers16203458 · Cited by 8
“HCC was confirmed by pathological samples or dynamic computed tomography (CT) or magnetic resonance imaging (MRI) according to AASLD guidance [2].”
BackgroundMethodInfluential
LI-RADS Ultrasound Surveillance Version 2024: Comparison With Version 2017 for Hepatocellular Carcinoma Detection and Risk Factors for Visualization Score C
Heo, S., Kim, S. Y., Lee, S. J., Lee, S. S., Byun, J. H., Won, H. J., Shin, Y. M., Choi, S. H., & Sirlin, C. B. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.24.32433 · Cited by 9
Genome-Wide Methylation Sequencing to Identify DNA Methylation Markers for Early-stage Hepatocellular Carcinoma in Liver and Blood
Fu, S., Boers, R., Boers, J., van der Meeren, P. E., Helmijr, J., de Weerd, V., Doukas, M., Jansen, M., Hansen, B. E., de Wilde, R. F., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03412-9 · Cited by 8
“Alpha-fetoprotein (AFP) is currently the only biomarker utilized for the detection and monitoring of HCC [5], but AFP testing has a sensitivity of only 39–64% for early-stage HCC [9].”
Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology
Alghamdi, S. A., & Al-hamoudi, W. (2023) · Cancers · doi:10.3390/cancers15215115 · Cited by 8
“Transarterial chemoembolization (TACE) is recommended as ﬁrst-line therapy for unresectable HCC and is used widely in the primary treatment of intermediate-stage disease [30,31].”
Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis
Ma, Y., Jiang, X., Song, P., & Tang, W. (2024) · BioScience Trends · doi:10.5582/bst.2023.01436 · Cited by 10
Impact of the Early COVID-19 Pandemic on Incidence and Outcomes of Hepatocellular Carcinoma in the United States
Liang, J., Lee, Y., Yeo, Y. H., Luu, M., Ayoub, W. S., Kuo, A., Trivedi, H. D., Vipani, A., Gaddam, S., Kim, H., et al. (2024) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000723 · Cited by 8
“Current practice guidelines recommend semiannual abdominal ultrasound with or without serum a -fetoprotein (AFP) for HCC surveillance among at-risk populations, such as those with chronic hepatitis B or liver cirrhosis (6,7).”
Self-citation
Radiofrequency ablation of hepatocellular carcinoma guided by real-time physics-based ablation simulation: a prospective study
Hoffer, E. K., Drinane, M. C., Bhatnagar, V., Mehta, R., Munger, D. P., & Borsic, A. (2024) · International Journal of Hyperthermia · doi:10.1080/02656736.2024.2331704 · Cited by 7
“Radiofrequency ablation (RFA) is a potentially curative minimally-invasive first-line therapy for unresectable small hepatocellular carcinoma (HCC) with low complication rates and rapid recovery [1,2].”
Risk Factors for Early Recurrence After Radical Resection of Hepatocellular Carcinoma Based on Preoperative Contrast-Enhanced Ultrasound and Clinical Features
Cao, K., Wu, L., Wang, X., Deng, H., Yuan, Y., Li, L., Xu, C., & Ye, X. H. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241281327 · Cited by 7
Optimizing US for HCC surveillance
Rodgers, S. K., Fetzer, D. T., Seow, J. H.-S., McGillen, K. L., Burrowes, D. P., Fung, C. I., Udare, A. S., Wilson, S. R., & Kamaya, A. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04631-y · Cited by 7
Do Risk Factors for HCC Impact the Association of CT/MRI LIRADS Major Features With HCC? An Individual Participant Data Meta-Analysis
Adamo, R. G., Lam, E., Salameh, J., van der Pol, C. B., Goins, S. M., Dawit, H., Costa, A. F., Levis, B., Singal, A. G., Chernyak, V., et al. (2024) · Canadian Association of Radiologists Journal · doi:10.1177/08465371241306297 · Cited by 7
“…diagnosis of HCC in “at-risk” populations which is defined as all individuals with chronic HBV, cirrhosis, or a personal history of HCC. 2,14 In summary, recent guidelines recommend that “low-risk” HBV-positive individuals should have a biopsy for HCC diagnosis, while LI-RADS allows…”
Self-citation
Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon’s Perspective
Zhu, X., Zhao, L., Li, B., Cheng, Y., & Sun, H. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s504457 · Cited by 7
“2,9,10,14 However, bevacizumab may induce an elevated risk of bleeding in patients with severe esophageal and gastric varices.”
Influential
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025
Kumar, K., & Saraswat, V. A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102547 · Cited by 10
AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction–associated steatotic liver disease
Fujiwara, N., Matsushita, Y., Tempaku, M., Tachi, Y., Kimura, G., Izuoka, K., Hayata, Y., Kawamura, S., Eguchi, A., Nakatsuka, T., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001360 · Cited by 10
Self-citation
Current Challenges in Imaging-Based Cancer Screening, From the AJR Special Series on Screening
Grimm, L. J., Kruse, D. E., Tailor, T. D., Johnson, K. S., Allen, B. C., & Ryser, M. D. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.32808 · Cited by 8
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology
Wajcman, D. I., Nicolàs, A., Picchio, C. A., van Selm, L., Dusheiko, G. M., Younossi, Z. M., Dillon, J. F., Alqahtani, S. A., Razavi, H. A., Colombo, M. G., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101436 · Cited by 8
“Despite most HCC guidelines emphasising the importance of hepatitis B virus vaccination and hepatitis C virus treatment, more emphasis is needed on viral hepatitis case detection, early treatment initiation, and preventive treatment, to reduce the risk of transmission and HCC. Viral hepatitis guidelines must underscor…”
Influential
Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST
Kim, H., Kim, B., Son, S. H., Jang, J. W., Sung, P. S., Choi, J. I., Kim, S. H., Oh, J. S., & Chun, H. J. (2025) · European Radiology · doi:10.1007/s00330-025-11730-x · Cited by 7
Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era
Chan, L. L., Chan, A. W. H., Yip, T. C., Wong, G. L., Ngai, A. K. H., Mo, F. K. F., Chok, K., Kung, J. W. C., Chu, C. M., Mok, K. K. S., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.028 · Cited by 7
Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study
Su, J., Huang, D., Liu, S., Xu, X., Chen, S.-C., Ou, J., Li, J., Yang, T., Li, W. X., Fan, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14219 · Cited by 7
“Individual studies [35–37] and consensus guidelines [2, 3] have indicated that potentially curative resection can improve prognosis of patients in stage C.”
“Hepatocellular carcinoma surveillance: Current challenges in Latin America”
Pagés, J., Mendizábal, M., Castro‐Narro, G., Menéndez, J. M., Beltrán, O., da Fonseca, L. G., Teller, J. P., Girala, M., Cano, D. F. A., & Piñero, F. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101935 · Cited by 8
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma
Meyers, B. M., Lim, H. J., Brahmania, M., Liu, D. M., Tam, V. C., McLeod, D., Ramjeesingh, R., Knox, J. J., & Vogel, A. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251357719 · Cited by 9
“3,44,149 HCC development can be a risk factor for liver decompensation 144,150 and HCC treatment has the potential to positively impact liver function by reducing tumor burden, delaying recurrence or progression or, more directly, by increasing liver remnant volume after resection in neoadjuvant…”
Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres
Sarwar, A., Nasser, I. A., Weinstein, J. L., Odeh, M., Babar, H. S., Dinh, D. C., Curry, M. P., Bullock, A. J., Eckhoff, D. E., Dib, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07471-0 · Cited by 7
“Out of the 28 patients, 18 were diagnosed based on imaging criteria [18 ], while 10 patients had biopsy-confirmed HCC.”
Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study
Zhang, N., Liu, K., Yu, Y., Yuan, K., Yu, H., Nault, J., Campani, C., Blaise, L., Mouri, S., Spitzer, E., et al. (2025) · Hepatology International · doi:10.1007/s12072-025-10895-3 · Cited by 7
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
Abaalkhail, F. A., Sanai, F. M., Alswat, K., Alzanbagi, A., Al-Jedai, A. H., Alshehri, A., Alfadda, A. A., Alghamdi, H., Almadi, M. A., AlEissa, M., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_199_25 · Cited by 8
Clinical and Imaging-Based Prognostic Models for Recurrence and Local Tumor Progression Following Thermal Ablation of Hepatocellular Carcinoma: A Systematic Review
Verhagen, C. A. M., Gholamiankhah, F., Buijsman, E. C. M., Broersen, A., van Erp, G. C. M., van der Velden, A. L., Rahmani, H., van der Leij, C., Brecheisen, R., Lanocita, R., et al. (2025) · Cancers · doi:10.3390/cancers17162656 · Cited by 7
“Therefore, clear and consistent definitions, as described in guidelines on definition of (time-to-event) endpoints [37,38] and international HCC management guidelines [2,39], are essential.”
Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis
Lim, R. Y., Tan, F. X. N., Ho, G. J. K., Tham, E. K. J., Kow, A. W. C., Lv, G., Fan, Z., Syn, N. L. X., Nakano, M., Li, W., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.036 · Cited by 7
Surgery Without Scalpel: Histotripsy as a Non-Invasive and Non-Thermal Modality for Liver Tumor Ablation
Paramythiotis, D., Tsavdaris, D., Tsavdaris, G., Hatzidakis, A. A., Psarras, K. K., Mekras, A., Georgiades, C. S., & Michalopoulos, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186391 · Cited by 7
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection
Tang, S.-C., Huang, T., Tang, R., Lin, K., Luo, C., Shen, Y., Zhang, K., Tang, Y., Kong, J., Chen, Z., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335449 · Cited by 7
LI-RADS CT/MRI Nonradiation Treatment Response Assessment Version 2024 for Detecting Local Recurrence of Surgically Resected Hepatocellular Carcinoma
Chiu, S.-H., Yoon, L. S., Altmayer, S., Delitto, D., Kamaya, A., & Tse, J. R. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.33787 · Cited by 7
Liver Steatosis‐Related Polygenic Risk Score Predicts Hepatocellular Carcinoma Risk After Hepatitis C Virus Eradication
Lin, Y., Lin, Y., Chen, Y., Chen, Y. A., Chen, I.-C., Tsai, H., Chen, C. H., Lee, S., Yang, H., & Lee, T. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70566 · Cited by 7
“The primary endpoint of this study was the occurrence of HCC, diagnosed by histopathological examinations or typical image findings based on the practice guidelines of the American Association for the Study of Liver Diseases (AASLD) [37].”
Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Berman, Z. T., la Garza‐Ramos, C. D., Montazeri, S., Malone, C. D., Sandow, T. A., Gimenez, J. M., Young, S., Fidelman, N. A., Pianka, K. T., Sher, A., et al. (2026) · Radiology · doi:10.1148/radiol.251923 · Cited by 7
A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma
Taggart, D. J., Mahajan, S., Gallant, M. A., Pinkoviezky, I., Xu, J., Sorg, A. J., Roberts, C. C., Slinkov, D., Gorospe, E. C., Mubarak, A., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.012 · Cited by 7
Is hepatectomy feasible for hepatocellular carcinoma patients with clinically significant portal hypertension and beyond the Milan criteria?
Lu, Z., Wei, X., Tan, L., Xiang, B., & Gong, W. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107073 · Cited by 9
Development and Evaluation of a Patient Cirrhosis Knowledge Assessment
Bloom, P. P., Zheng, C., Hyde, A. M., Johnson, E., Cruz, A. M., Carbonneau, M., Hazra, D., & Tandon, P. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08238-z · Cited by 7
Comparison of outcomes following surgical resection, percutaneous ablation or stereotactic body radiation therapy in early‐stage, solitary and small (≤3 cm) treatment‐naïve hepatocellular carcinoma
Maher, A. M., Shanker, M., Liu, H. Y.-H., Lee, Y., Leggett, D., Hodgkinson, P., Pryor, D. I., & Stuart, K. A. (2024) · Cancer Medicine · doi:10.1002/cam4.6978 · Cited by 7
“14,15 With the inclusion of SBRT as an alternative first-line treatment option within our MDM, 90% of the original 123 patients identified with BCLC early-stage solitary ≤ 3 cm HCC received a curative intent first-line therapy and only 5% received treatment stage migration therapy with TACE.”
Background
Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study
Huang, H., Liao, W., Zhang, K., Wang, H., Cheng, Q., & Mei, B. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s455878 · Cited by 7
“15,16 However, to the best of our knowledge, there is still no study about PA-TACE plus adjuvant immunotherapy for huge HCC.”
Background
Why Liver Cancer Hits Home: Bridging Healthcare Disparities in the Asian American and Pacific Islander Community
Li, D., Cheng, S., Woods, A. W., Luong, A., Schiltz, S., Tan, R., & Chi, Z. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s467913 · Cited by 7
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
Mak, L. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.08.03 · Cited by 7
“…scan with or without serum alpha feto-protein (AFP) measurement every 6 months among CHB patients with cirrhosis or risk factors for HCC. 5,44 Risk factors for HCC vary between regions, but in general refer to cirrhosis, men ≥ 40 years old or women ≥ 50 years old, or family history of HCC.”
Background
The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives
Celsa, C., Quartararo, A., Maida, M. F., Giusino, G., Gaudioso, V., Sparacino, A., Cusimano, G., Rao, S., Grova, A., Ciccia, R., et al. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.126 · Cited by 7
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
Starnawski, P., Nowak, K., Augustyn, Z., Malicki, D., Piąta, A., Lorek, D., & Janczura, J. (2025) · Medical Oncology · doi:10.1007/s12032-025-02674-9 · Cited by 9
“Additionally, AASLD suggests combining ultrasound with alpha-fetoprotein (AFP) measurement, which increases sensitivity from 53 to 63% compared to ultrasound alone [56, 57]”
Racial and ethnic differences in social determinants of health among patients with HCC
Al-Hasan, M., Rich, N. E., Figueroa, G., Garces, S. M., Quirk, L., Yekkaluri, S., Yopp, A. C., Jones, P. D., & Singal, A. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000735 · Cited by 7
“[18] Patients with a history of previously treated HCC, overt hepatic encephalopathy precluding survey completion, or primary language other than English or Spanish were excluded.”
Self-citation
Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review
Jeong, W. K. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.08.25 · Cited by 7
“Over the past two decades, various medical societies have proposed imaging-based criteria and guidelines for diagnosing HCC. 1,4 These systems originated from Europe, Asia, and North America; thus, inconsistencies led to regional differences and hindered the global adoption of a single guideline.”
Background
Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation
Burgio, M. D., Garzelli, L., Cannella, R., Ronot, M., & Vilgrain, V. (2023) · Life · doi:10.3390/life13122267 · Cited by 7
“This list of tips is provided to synthetize the reported evidence and to give practical recommendations:”
Application of Machine Learning Techniques to Assess Alpha-Fetoprotein at Diagnosis of Hepatocellular Carcinoma
Gil-Rojas, S., Suárez, M., Martínez-Blanco, P., Torres, A., Martínez-García, N., Blasco, P., Torralba, M., & Mateo, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041996 · Cited by 8
“This is because different geographic areas have distinct risk factors that can modify the course and prognosis of the disease [9,10].”
Background
From research to reality: The role of artificial intelligence applications in HCC care
Wiest, I. C., Gilbert, S., & Kather, J. N. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000136 · Cited by 7
The Future Role of Abdominal US in Hepatocellular Carcinoma Surveillance
Mendiratta‐Lala, M., Fetzer, D. T., Kamaya, A., Parikh, N. D., & Singal, A. G. (2024) · Radiology · doi:10.1148/radiol.232624 · Cited by 7
Self-citation
Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis
Danzeng, A., Guo, L., Yang, Z., He, Z.-W., Zeng, C., Ciren, P., Lan, R.-H., Jiang, X., Wang, C., & Zhang, B. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.05.001 · Cited by 6
Do low skeletal muscle bulk and disturbed body fat mass impact tumor recurrence in stage I/II hepatocellular carcinoma undergoing surgery? An observational cohort study
Lee, C., Tsai, H., Hsu, H.-M., Yu, M., Lee, W., Wang, C., Hsieh, Y., Lin, C.-Y., Cheng, M., Lo, C.-J., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001905 · Cited by 6
Extracellular Vesicles, Circadian Rhythms, and Cancer: A Comprehensive Review with Emphasis on Hepatocellular Carcinoma
Fekry, B., Ugartemendia, L., Esnaola, N. F., & Goetzl, L. M. (2024) · Cancers · doi:10.3390/cancers16142552 · Cited by 6
“…biomarker currently validated for clinical use for screening for HCC, alpha-fetoprotein (AFP), has marginal sensitivity and specificity (approximately 60 and 80%, respectively); not surprisingly, most societal guidelines recommend its use only in combination with abdominal ultrasound [32,34–36].”
Background
Quality of care in hepatocellular carcinoma—A critical review
Abdelmalak, J., Lubel, J. S., Sinclair, M. J., Majeed, A., Kemp, W. W., & Roberts, S. K. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000595 · Cited by 6
“[47,48] 10] Australian QI therefore suggests that TACE (or alternative therapies such as selective internal radioembolization therapy) is offered to patients with BCLC-B HCC not suitable for curative treatment with the intent to delay progression and prolong survival, and in a select subset of…”
Influential
The Clinical Utility of Liver-Specific Ultrasound Contrast Agents During Hepatocellular Carcinoma Imaging
Hawley, J., Tang, Y., Sjöström, A., Fuentes‐Alburo, A., & Tranquart, F. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.10.011 · Cited by 6
Feasibility and safety of minimally invasive R1 vascular surgery for hepatocellular carcinoma: a cohort study
Abdelhadi, S., Șandra-Petrescu, F., Vassilev, G., Birgin, E., Rahbari, N. N., & Reissfelder, C. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-11476-5 · Cited by 6
Hepatocellular Carcinoma: Imaging Advances in 2024 with a Focus on Magnetic Resonance Imaging
Renzulli, M., & Giampalma, E. (2025) · Current Oncology · doi:10.3390/curroncol32010040 · Cited by 6
Radiation Segmentectomy or Ablative External Beam Radiation Therapy as Initial Treatment for Solitary Hepatocellular Carcinoma: A Multicenter Experience
la Garza‐Ramos, C. D., Montazeri, S. A., LeGout, J. D., Lewis, A. R., Frey, G. T., Paz‐Fumagalli, R., Hallemeier, C. L., Rutenberg, M. S., Ashman, J. B., & Toskich, B. B. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s507267 · Cited by 6
Future perspectives on immunotherapy for hepatocellular carcinoma
Chan, L. L., & Chan, S. L. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323199 · Cited by 7
“4 Given these outcomes, ICI-based treatment is now the standard first-line therapy for patients with advanced HCC. 6,7 It has long been recognized that the immune sys-tem plays a substantial role in cancer control.”
Rising Incidence of Early-Onset Liver Cancer and Intrahepatic Bile Duct Cancer: Analysis of the National Childhood Cancer Registry Database
Danpanichkul, P., Pang, Y., Auttapracha, T., Ta’ani, O. A., Suenghataiphorn, T., Kaewdech, A., Muthiah, M. D., Kim, D., Wijarnpreecha, K., Singal, A. G., et al. (2025) · Cancers · doi:10.3390/cancers17071133 · Cited by 6
“Expanding data collection to include these states in future cycles would provide a more comprehensive understanding of childhood liver cancer epidemiology and regional variations [17].”
Self-citation
Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies
Tang, H.-H., Zhang, M., Zhang, Z.-C., Chen, F., Li, S., Chen, W., & Wang, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-13993-5 · Cited by 6
“The diversification of systemic anti-tumor agents has changed the therapeutic landscape for advanced HCC [3, 4].”
Comparison of Gadoxetic Acid-enhanced Liver MRI and Contrast-enhanced CT for the Noninvasive Diagnosis of Hepatocellular Carcinoma
Yoon, J. H., Chang, W., Kim, Y. K., Lee, C. H., Kim, J. W., Park, B. J., Choi, J., Kim, S., Park, H. S., Lee, E. S., et al. (2025) · Liver Cancer · doi:10.1159/000545965 · Cited by 6
An automated machine-learning model for prognostic risk stratification of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization
An, C., Zuo, M., Li, W., & Wu, P. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002719 · Cited by 6
“As previously reported, HCC was diagnosed either through histological biopsy or according to the European Association for the Study of the Liver criteria [21] .”
Validation of the Toronto recurrence inference using machine-learning for post-transplant hepatocellular carcinoma model
Li, Z., Chen, I. C.-Y., Centonze, L., Magyar, C. T. J., Choi, W. J., Ivanics, T., O'Kane, G. M., Vogel, A., Erdman, L., Carlis, L. G. D., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00994-5 · Cited by 6
“Liver transplantation (LT) represents the optimal treatment for patients with early-stage hepatocellular carcinoma (HCC) 1,2 .”
Self-citation
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study
Chun, H. S., Lee, M., Lee, H. A., Park, E. S., Choi, J. Y., Baek, H. S., Kim, T. H., Lin, H., Yip, T. C., Lee, H. W., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.025 · Cited by 9
“8,12 Considering the relatively low HCC incidence in the MASLD population compared with other chronic liver diseases, 6 the risk model was developed to stratify patients with an annual HCC incidence 0.2%, potentially exempting them from HCC surveillance.”
Influential
Shallow whole-genome sequencing of circulating tumour DNA predicts clinical outcomes to systemic therapy in advanced hepatocellular carcinoma
Mallela, V. R., Alharbi, S. N., Vithayathil, M. K., Ward, C., Patel, R., & Sharma, R. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115633 · Cited by 6
Preventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies
Joo, I. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.07.29 · Cited by 6
Modern approach to hepatocellular carcinoma treatment
Cortese, F., Anagnostopoulos, F., Bazzocchi, M. V., Caringi, S., Pisani, A. R., Renzulli, M., Paraskevopoulos, I. T., Laera, L., Surgo, A., Spiliopoulos, S., et al. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.107873 · Cited by 6
Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines
Mino, M., Kakazu, E., & Kanto, T. (2025) · Gut and Liver · doi:10.5009/gnl250187 · Cited by 6
Performance of the multi-target hepatocellular carcinoma blood test: Design and rationale of the ALTUS study
John, B. V., Camardo, M., Porter, K. M., Elias, P. Z., Kielar‐Grevstad, E., Rego, S. P., Parikh, N. D., Roberts, L. R., Silva, A. C., Singal, A. G., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000800 · Cited by 6
Self-citation
Machine learning-based hepatocellular carcinoma risk prediction model for patients with HBV-related compensated advanced chronic liver disease
Li, Y., Qiao, Z., Li, Y., Feng, Y., & Wang, X. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06345-0 · Cited by 6
Hepatocellular carcinoma (HCC): An update on risk factors, surveillance, diagnosis and treatment strategies
Mathew, S., Cussens, D., & Pericleous, M. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100532 · Cited by 6
“Prognostic scores, such as the aMAP score, 20 and speciﬁc scores in hepatitis B (PAGE-B) 5 , 21 , 22 may help target surveillance to higher-risk individuals, and it remains important to consider individual factors, including co-existing aetiologies towards liver disease.”
Pathological Complete Response after Systemic Therapy and Curative Resection in Initially Unresectable Hepatocellular Carcinoma: Feasibility of a Tumor-Free with Drug-Free Strategy
Lin, Q., Peng, W., Yu, X., Xie, F., Wang, X., Song, Z., Luo, M., Yang, Z., Hu, Z., Fu, Y., et al. (2025) · Liver Cancer · doi:10.1159/000549793 · Cited by 6
“Inclusion criteria were as follows: (1) HCC diagnosed per American Association for the Study of Liver Diseases (AASLD) guidelines [18]; (2) no extrahepatic metastasis; (3) no prior exposure to systemic treatment; (4) initially un-resectable disease rendered resectable by systemic therapy; (5)…”

Authors: Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
Affiliations: The University of Texas Southwestern Medical Center (US)
Institució Catalana de Recerca i Estudis Avançats (ES)
Johns Hopkins University (US)
University of California, San Francisco (US)
Mayo Clinic (US)
University Health Network (CA)
Oregon Health & Science University (US)
Northwestern Medical Faculty Foundation (US)
University of California, Los Angeles (US)
University of Pennsylvania (US)
Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Vanderbilt University Medical Center (US)
Medical College of Wisconsin (US)
Stanford Medicine (US)
Memorial Sloan Kettering Cancer Center (US)
Yale University (US)
Corresponding author: Singal, Amit G.
ORCID: Singal, Amit G.
Llovet, Josep M.
Yarchoan, Mark
Mehta, Neil
Heimbach, Julie K.
Dawson, Laura A.
Jou, Janice H.
Kulik, Laura M.
Agopian, Vatche G.
Marrero, Jorge A.
Brown, Daniel B.
Goyal, Lipika
Wei, Alice C.
Taddei, Tamar H.
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2023-05-22
Volume: 78
Issue: 6
Pages: 1922-1965
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1097/hep.0000000000000466
PMC: PMC10663390
OpenAlex: W4377011124
Cited by: 2,052
References: 341
Citations by year: 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
FWCI: 346.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
American Association for the Study of Liver Diseases
Gilead Sciences
Boston Scientific Corporation
Exelixis
Incyte
Cancer Research UK (26813)
Eisai
Ipsen
Sirtex Medical
National Institutes of Health (UL1TR001863)
Genentech
National Cancer Institute (P50CA062924, R01CA285544)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords: hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
MeSH terms: Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks